TrialClinical and translational science2026

First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASP1617, a Cathepsin-S Inhibitor, in Healthy Adult Subjects.

Tomoki Kojima et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.